日付 | 受信時刻 | ニュースソース | 見出し | コード | 企業名 |
2024/05/25 | 05 : 46 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of 1933 | NASDAQ:CLRB | Cellectar Biosciences Inc |
2024/05/16 | 19 : 05 | Edgar (US Regulatory) | Form DEFR14A - Revised definitive proxy soliciting materials | NASDAQ:CLRB | Cellectar Biosciences Inc |
2024/05/14 | 19 : 45 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:CLRB | Cellectar Biosciences Inc |
2024/05/14 | 19 : 40 | GlobeNewswire Inc. | Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update | NASDAQ:CLRB | Cellectar Biosciences Inc |
2024/05/14 | 19 : 32 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:CLRB | Cellectar Biosciences Inc |
2024/05/08 | 19 : 40 | GlobeNewswire Inc. | Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day | NASDAQ:CLRB | Cellectar Biosciences Inc |
2024/05/07 | 19 : 40 | GlobeNewswire Inc. | Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024 | NASDAQ:CLRB | Cellectar Biosciences Inc |
2024/03/27 | 19 : 40 | GlobeNewswire Inc. | Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update | NASDAQ:CLRB | Cellectar Biosciences Inc |
2024/03/20 | 19 : 40 | GlobeNewswire Inc. | Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024 | NASDAQ:CLRB | Cellectar Biosciences Inc |
2024/03/14 | 21 : 52 | GlobeNewswire Inc. | Cellectar Biosciences to Present at the 36th Annual Roth Conference | NASDAQ:CLRB | Cellectar Biosciences Inc |
2024/03/04 | 20 : 40 | GlobeNewswire Inc. | Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer | NASDAQ:CLRB | Cellectar Biosciences Inc |
2024/02/15 | 10 : 31 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:CLRB | Cellectar Biosciences Inc |
2024/02/15 | 06 : 29 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:CLRB | Cellectar Biosciences Inc |
2024/02/07 | 20 : 40 | GlobeNewswire Inc. | Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference | NASDAQ:CLRB | Cellectar Biosciences Inc |
2024/02/02 | 20 : 03 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:CLRB | Cellectar Biosciences Inc |
2024/01/31 | 22 : 00 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:CLRB | Cellectar Biosciences Inc |
2024/01/30 | 20 : 40 | GlobeNewswire Inc. | Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study | NASDAQ:CLRB | Cellectar Biosciences Inc |
2024/01/26 | 06 : 30 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:CLRB | Cellectar Biosciences Inc |
2024/01/25 | 20 : 40 | GlobeNewswire Inc. | Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million | NASDAQ:CLRB | Cellectar Biosciences Inc |
2024/01/22 | 20 : 40 | GlobeNewswire Inc. | Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient | NASDAQ:CLRB | Cellectar Biosciences Inc |
2024/01/16 | 20 : 40 | GlobeNewswire Inc. | Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data | NASDAQ:CLRB | Cellectar Biosciences Inc |
2024/01/12 | 20 : 44 | GlobeNewswire Inc. | Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results | NASDAQ:CLRB | Cellectar Biosciences Inc |
2024/01/11 | 20 : 40 | GlobeNewswire Inc. | Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting | NASDAQ:CLRB | Cellectar Biosciences Inc |
2024/01/09 | 20 : 02 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:CLRB | Cellectar Biosciences Inc |
2024/01/08 | 20 : 30 | GlobeNewswire Inc. | Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom’s Macroglobulinemia | NASDAQ:CLRB | Cellectar Biosciences Inc |
2024/01/03 | 22 : 30 | GlobeNewswire Inc. | Cellectar Biosciences to Announce Top-line Data from WM Pivotal Trial on January 8, 2024 | NASDAQ:CLRB | Cellectar Biosciences Inc |
2023/12/19 | 22 : 30 | GlobeNewswire Inc. | Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation | NASDAQ:CLRB | Cellectar Biosciences Inc |
2023/12/13 | 10 : 09 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:CLRB | Cellectar Biosciences Inc |
2023/12/13 | 10 : 07 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:CLRB | Cellectar Biosciences Inc |
2023/12/13 | 10 : 05 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:CLRB | Cellectar Biosciences Inc |